Single Particle Characterization to Guide LNP Pre-Formulation for Emerging mRNA Modalities

• Applying single particle analysis to understand heterogeneity in LNP size, charge, and encapsulation efficiency, and why this matters for reproducibility
• Using particle-level insights to de-risk pre-formulation decisions in novel modalities (e.g., self-amplifying RNA, circular RNA, gene editing payloads)
• Linking particle attributes to critical quality attributes (CQAs) such as potency, immunogenicity, and stability to support early stage development

Speakers:

Bohdan Andreiuk

Senior Scientist, New Modality Preformulation & LNP Formulation

AstraZeneca